These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The study of immunotherapy of ovarian carcinoma with anti-idiotypic antibody].
    Author: Wang J, Qian H, Feng J.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 1996 Jun; 31(6):353-6. PubMed ID: 9206171.
    Abstract:
    OBJECTIVES: To study the role of anti-idiotypic antibody in immunotherapy of ovarian carcinoma, and to investigate the effect of anti-idiotypic antibody (Ab2) on ovarian carcinoma in vivo. METHODS: Six to eight week-old female BCF1 mice were immunized three times at 28 days intervals with 50-100 micrograms of anti-idiotypic antibody Ab2 of ovarian carcinoma. The initial immunization was given with complete Freund's adjuvant (CFA), followed by incomplete Freund's adjuvant (IFA). The control mice were immunized with normal mouse IgG. The ovarian carcinoma cells (SKOV3) passaged from nude mice were transplanted to the subrenal capsules of immunized BCF1 mice after the last injection. Then the mice were bred separately on the 2nd, 4th, 6th, 8th and 10th days after the transplantation operations. Specific anti-Ab2(Ab3) in sera was detected by using inhibition assay of enzyme-linked immunospecific assay. Tumor infilitration lymphocytes (TIL) and tumor cells from the tumor tissue of BCF1 were observed microscopically. RESULTS: The sera levels of Ab3 in Ab2 immunized mice were higher than those of the controls. TIL in the former were found to reach their highest peak on the 6th day, where as the highest peak for the controls was on the 8-10th days, tumor cell viability rate in the former decreased rapidly after 6 days, but in the controls decreased only gradually. CONCLUSIONS: Ab2 could induce specific immuno rejection to ovarian carcinoma in vivo. It is predicted that anti-idiotypic antibody Ab2 might be used in immunotherapy of ovarian cancer patients and also as a preventive for post treatment clinical recurrence of ovarian carcinoma.
    [Abstract] [Full Text] [Related] [New Search]